FiercePharma

Ligand's Pelthos unit joins forces with Channel Therapeutics in merger centered on launch of molluscum gel Zelsuvmi

Ligand Pharmaceuticals’ topical skin infection gel Zelsuvmi is changing hands again—sort of. After Ligand last year created Pelthos Therapeutics to support the launch of Zelsuvmi, Pelthos is now ...
Seeking Alpha

Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward

I maintain my Buy rating on Ligand Pharmaceuticals due to its strong growth trajectory and diversified portfolio. Ligand offers investors exposure to dozens of therapies, reducing risk and increasing ...
Nasdaq

Ligand (LGND) Posts Long-Term Outlook, Updates Portfolio Progress

At its R&D event held on Dec 12, Ligand Pharmaceuticals LGND provided an overview of its business model and issued fresh guidance outlook for the next five years. Ligand issued fresh guidance for 2024 ...
ascopubs.org

Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or ...

Germline Pathogenic/Likely Pathogenic Mutations and Subsequent Neoplasms Among Childhood Cancer Survivors: A Report From the Children's Oncology Group ALTE03N1 Study Patients received escalating ...